SGC2085 is a potent and selective inhibitor of the protein arginine methyltransferase PRMT8, which plays a role in epigenetic regulation and cellular signaling. Its primary application lies in research settings, particularly in the study of epigenetic mechanisms and their influence on gene expression and cell behavior. Due to its selectivity for PRMT8, SGC2085 is used as a chemical probe to dissect the biological functions of this enzyme in neuronal development and function, as PRMT8 is predominantly expressed in the central nervous system. Researchers use SGC2085 to investigate the role of PRMT8 in brain-related disorders, including neurodegenerative diseases and psychiatric conditions. It also supports drug discovery efforts by helping validate PRMT8 as a therapeutic target. Additionally, SGC2085 contributes to understanding the broader family of PRMT enzymes and their involvement in cancer, where aberrant methylation events can drive disease progression. Its application remains mainly confined to in vitro and cellular assays in academic and pharmaceutical research.